These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 25997113)

  • 21. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression.
    Keiser PB; Biggs-Cicatelli S; Moran EE; Schmiel DH; Pinto VB; Burden RE; Miller LB; Moon JE; Bowden RA; Cummings JF; Zollinger WD
    Vaccine; 2011 Feb; 29(7):1413-20. PubMed ID: 21199704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid characterization of outer-membrane proteins in Neisseria lactamica by SELDI-TOF-MS (surface-enhanced laser desorption ionization-time-of-flight MS) for use in a meningococcal vaccine.
    Mukhopadhyay TK; Halliwell D; O'Dwyer C; Shamlou PA; Levy MS; Allison N; Gorringe A; Reddin KM
    Biotechnol Appl Biochem; 2005 Apr; 41(Pt 2):175-82. PubMed ID: 15315478
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative proteomics reveals distinct differences in the protein content of outer membrane vesicle vaccines.
    van de Waterbeemd B; Mommen GP; Pennings JL; Eppink MH; Wijffels RH; van der Pol LA; de Jong AP
    J Proteome Res; 2013 Apr; 12(4):1898-908. PubMed ID: 23410224
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined.
    Biagini M; Spinsanti M; De Angelis G; Tomei S; Ferlenghi I; Scarselli M; Rigat F; Messuti N; Biolchi A; Muzzi A; Anderloni G; Brunelli B; Cartocci E; Buricchi F; Tani C; Stella M; Moschioni M; Del Tordello E; Colaprico A; Savino S; Giuliani MM; Delany I; Pizza M; Costantino P; Norais N; Rappuoli R; Masignani V
    Proc Natl Acad Sci U S A; 2016 Mar; 113(10):2714-9. PubMed ID: 26888286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines.
    Donnelly J; Medini D; Boccadifuoco G; Biolchi A; Ward J; Frasch C; Moxon ER; Stella M; Comanducci M; Bambini S; Muzzi A; Andrews W; Chen J; Santos G; Santini L; Boucher P; Serruto D; Pizza M; Rappuoli R; Giuliani MM
    Proc Natl Acad Sci U S A; 2010 Nov; 107(45):19490-5. PubMed ID: 20962280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease.
    Su EL; Snape MD
    Expert Rev Vaccines; 2011 May; 10(5):575-88. PubMed ID: 21604979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB).
    Bettinger JA; Scheifele DW; Halperin SA; Vaudry W; Findlow J; Borrow R; Medini D; Tsang R;
    Vaccine; 2013 Dec; 32(1):124-30. PubMed ID: 23588089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent developments in vaccines to prevent meningococcal serogroup B infections.
    Vermont CL; van den Dobbelsteen GP; de Groot R
    Curr Opin Mol Ther; 2003 Feb; 5(1):33-8. PubMed ID: 12669468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of the protein content of a meningococcal outer membrane vesicle vaccine by polyacrylamide gel electrophoresis and mass spectrometry.
    Vipond C; Wheeler JX; Jones C; Feavers IM; Suker J
    Hum Vaccin; 2005; 1(2):80-4. PubMed ID: 17038831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Vaccinal strategies in response to new epidemiological challenges in 2010. Reasonable hope for a "B" meningococcal vaccine].
    Nicolas P
    Med Trop (Mars); 2010 Aug; 70(4):325-32. PubMed ID: 22368926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines.
    Sanders H; Feavers IM
    Expert Rev Vaccines; 2011 Mar; 10(3):323-34. PubMed ID: 21434800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months.
    Wong S; Lennon D; Jackson C; Stewart J; Reid S; Crengle S; Tilman S; Aaberge I; O'Hallahan J; Oster P; Mulholland K; Martin D
    Pediatr Infect Dis J; 2007 Apr; 26(4):345-50. PubMed ID: 17414400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate.
    Delgado M; Yero D; Niebla O; González S; Climent Y; Pérez Y; Cobas K; Caballero E; García D; Pajón R
    Vaccine; 2007 Dec; 25(50):8420-31. PubMed ID: 17996338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines.
    Tunheim G; Arnemo M; Næss LM; Fjeldheim ÅK; Nome L; Bolstad K; Aase A; Mandiarote A; González H; González D; García L; Cardoso D; Norheim G; Rosenqvist E
    Vaccine; 2013 Dec; 31(51):6097-106. PubMed ID: 24120679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bexsero: a multicomponent vaccine for prevention of meningococcal disease.
    Gorringe AR; Pajón R
    Hum Vaccin Immunother; 2012 Feb; 8(2):174-83. PubMed ID: 22426368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine.
    Bai X; Borrow R
    Expert Rev Vaccines; 2010 Oct; 9(10):1203-17. PubMed ID: 20923270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variability of genes encoding surface proteins used as vaccine antigens in meningococcal endemic and epidemic strain panels from Norway.
    Holst J; Comanducci M; Bambini S; Muzzi A; Comandi S; Oksnes J; DeTora L; Pizza M; Rappuoli R; Caugant DA
    Vaccine; 2014 May; 32(23):2722-31. PubMed ID: 24631075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Challenges and progress in the development of a serogroup B meningococcal vaccine.
    Lewis S; Sadarangani M; Hoe JC; Pollard AJ
    Expert Rev Vaccines; 2009 Jun; 8(6):729-45. PubMed ID: 19485754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease.
    Fredriksen JH; Rosenqvist E; Wedege E; Bryn K; Bjune G; Frøholm LO; Lindbak AK; Møgster B; Namork E; Rye U
    NIPH Ann; 1991 Dec; 14(2):67-79; discussion 79-80. PubMed ID: 1812438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen.
    Seib KL; Scarselli M; Comanducci M; Toneatto D; Masignani V
    Expert Rev Vaccines; 2015 Jun; 14(6):841-59. PubMed ID: 25704037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.